When to Treat First in Metastatic NSCLC? - Takeaways - MDSpire
Advertisement
When to Treat First in Metastatic NSCLC?
Real-world data show flexible sequencing of immunotherapy and local radical treatment can achieve durable survival in selected patients with synchronous oligometastatic NSCLC
Both upfront and delayed local radical treatment (LRT) combined with immune checkpoint inhibitors (ICI) yield a three-year overall survival of approximately 45%.
2
Favorable prognostic factors for better overall survival include good performance status, non-squamous histology, and high PD-L1 expression.
3
Patients with brain metastases demonstrated better outcomes compared to those with bone or other metastatic sites.
4
The study emphasizes the importance of patient selection over strict adherence to treatment sequencing in metastatic NSCLC.
5
No definitive conclusion on optimal sequencing of ICI and LRT was reached, highlighting the need for individualized treatment approaches.
